Cargando...
Antiangiogenic and antitumor activity of LP-261, a novel oral tubulin binding agent, alone and in combination with bevacizumab
LP-261 is a novel tubulin targeting anticancer agent that binds at the colchicine site on tubulin, inducing G2/M arrest. Screening in the NC160 cancer cell lines resulted in a mean G150 of approximately 100 nM. Here, we report the results of testing in multiple mouse xenograft models and angiogenesi...
Gardado en:
| Publicado en: | Invest New Drugs |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
2010
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6446042/ https://ncbi.nlm.nih.gov/pubmed/20820910 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-010-9520-5 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|